Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 280 entries
Sorted by: Best Match Show Resources per page
Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease.

Clinical and translational gastroenterology

Epstein M, Johnson DA, Hawes R, Schmulewitz N, Vanagunas AD, Gossen ER, Robieson WZ, Eaton S, Dubow J, Chatamra K, Benesh J.
PMID: 27030949
Clin Transl Gastroenterol. 2016 Mar 31;7:e159. doi: 10.1038/ctg.2016.19.

OBJECTIVES: The objectives of this study were to present procedure- and device-associated adverse events (AEs) identified with long-term drug delivery via percutaneous endoscopic gastrojejunostomy (PEG-J). Levodopa-carbidopa intestinal gel (LCIG, also known in US as carbidopa-levodopa enteral suspension, CLES) is...

Cite
Epstein M, Johnson DA, Hawes R, et al. Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease. Clin Transl Gastroenterol. 2016;7:e159doi: 10.1038/ctg.2016.19.
Epstein, M., Johnson, D. A., Hawes, R., Schmulewitz, N., Vanagunas, A. D., Gossen, E. R., Robieson, W. Z., Eaton, S., Dubow, J., Chatamra, K., & Benesh, J. (2016). Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease. Clinical and translational gastroenterology, 7e159. https://doi.org/10.1038/ctg.2016.19
Epstein, Michael, et al. "Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease." Clinical and translational gastroenterology vol. 7 (2016): e159. doi: https://doi.org/10.1038/ctg.2016.19
Epstein M, Johnson DA, Hawes R, Schmulewitz N, Vanagunas AD, Gossen ER, Robieson WZ, Eaton S, Dubow J, Chatamra K, Benesh J. Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease. Clin Transl Gastroenterol. 2016 Mar 31;7:e159. doi: 10.1038/ctg.2016.19. PMID: 27030949; PMCID: PMC4822096.
Copy Download .nbib Format: NLM
Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism.

Journal of clinical and diagnostic research : JCDR

Merajoth AL, Pillai PS, Iype T.
PMID: 27437241
J Clin Diagn Res. 2016 May;10(5):FC07-10. doi: 10.7860/JCDR/2016/16043.7886. Epub 2016 May 01.

INTRODUCTION: Parkinson's disease is the most common form of a group of progressive neurodegenerative disorders. The use of levodopa as dopamine - replacement therapy is highly effective in ameliorating the symptoms of the disease and remains the standard drug...

Cite
Merajoth AL, Pillai PS, Iype T. Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism. J Clin Diagn Res. 2016;10(5):FC07-10doi: 10.7860/JCDR/2016/16043.7886.
Merajoth, A. L., Pillai, P. S., & Iype, T. (2016). Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism. Journal of clinical and diagnostic research : JCDR, 10(5), FC07-10. https://doi.org/10.7860/JCDR/2016/16043.7886
Merajoth, Abhijith Lalesh, et al. "Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism." Journal of clinical and diagnostic research : JCDR vol. 10,5 (2016): FC07-10. doi: https://doi.org/10.7860/JCDR/2016/16043.7886
Merajoth AL, Pillai PS, Iype T. Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism. J Clin Diagn Res. 2016 May;10(5):FC07-10. doi: 10.7860/JCDR/2016/16043.7886. Epub 2016 May 01. PMID: 27437241; PMCID: PMC4948417.
Copy Download .nbib Format: NLM
Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.

Therapeutic advances in neurological disorders

Virhammar J, Nyholm D.
PMID: 28344656
Ther Adv Neurol Disord. 2017 Mar;10(3):171-187. doi: 10.1177/1756285616681280. Epub 2016 Dec 01.

The duration of action of oral levodopa becomes shorter as Parkinson's disease (PD) progresses. Patients with advanced PD may develop potentially disabling motor fluctuations and abnormal involuntary movement (dyskinesia), which cannot be managed with optimized oral or transdermal PD...

Cite
Virhammar J, Nyholm D. Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience. Ther Adv Neurol Disord. 2016;10(3):171-187doi: 10.1177/1756285616681280.
Virhammar, J., & Nyholm, D. (2017). Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience. Therapeutic advances in neurological disorders, 10(3), 171-187. https://doi.org/10.1177/1756285616681280
Virhammar, Johan, and Nyholm, Dag. "Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience." Therapeutic advances in neurological disorders vol. 10,3 (2017): 171-187. doi: https://doi.org/10.1177/1756285616681280
Virhammar J, Nyholm D. Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience. Ther Adv Neurol Disord. 2017 Mar;10(3):171-187. doi: 10.1177/1756285616681280. Epub 2016 Dec 01. PMID: 28344656; PMCID: PMC5349373.
Copy Download .nbib Format: NLM
Automatic behavior and communication due to pramipexole.

Journal of clinical movement disorders

Walker RH.
PMID: 27403333
J Clin Mov Disord. 2016 Jul 11;3:9. doi: 10.1186/s40734-016-0038-7. eCollection 2016.

A 45-year-old woman reported automatic behaviors and communication whilst she was being treated with pramipexole. These episodes vanished after the medication was tapered and she was started on levodopa/carbidopa. I hypothesize that the episodes were related to disordered awareness...

Cite
Walker RH. Automatic behavior and communication due to pramipexole. J Clin Mov Disord. 2016;3:9doi: 10.1186/s40734-016-0038-7.
Walker, R. H. (2016). Automatic behavior and communication due to pramipexole. Journal of clinical movement disorders, 39. https://doi.org/10.1186/s40734-016-0038-7
Walker, Ruth H. "Automatic behavior and communication due to pramipexole." Journal of clinical movement disorders vol. 3 (2016): 9. doi: https://doi.org/10.1186/s40734-016-0038-7
Walker RH. Automatic behavior and communication due to pramipexole. J Clin Mov Disord. 2016 Jul 11;3:9. doi: 10.1186/s40734-016-0038-7. eCollection 2016. PMID: 27403333; PMCID: PMC4939520.
Copy Download .nbib Format: NLM
Comprehensive treatment of dementia with Lewy bodies.

Alzheimer's research & therapy

Boot BP.
PMID: 26029267
Alzheimers Res Ther. 2015 May 29;7(1):45. doi: 10.1186/s13195-015-0128-z. eCollection 2015.

Dementia with Lewy bodies is an under-recognized disease; it is responsible for up to 20 % of all dementia cases. Accurate diagnosis is essential because the management of dementia with Lewy bodies is more complex than many neurodegenerative diseases....

Cite
Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther. 2015;7(1):45doi: 10.1186/s13195-015-0128-z.
Boot, B. P. (2015). Comprehensive treatment of dementia with Lewy bodies. Alzheimer's research & therapy, 7(1), 45. https://doi.org/10.1186/s13195-015-0128-z
Boot, Brendon P. "Comprehensive treatment of dementia with Lewy bodies." Alzheimer's research & therapy vol. 7,1 (2015): 45. doi: https://doi.org/10.1186/s13195-015-0128-z
Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther. 2015 May 29;7(1):45. doi: 10.1186/s13195-015-0128-z. eCollection 2015. PMID: 26029267; PMCID: PMC4448151.
Copy Download .nbib Format: NLM
Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo.

Journal of neurochemistry

Harun R, Hare KM, Brough EM, Munoz MJ, Grassi CM, Torres GE, Grace AA, Wagner AK.
PMID: 26611352
J Neurochem. 2016 Mar;136(6):1270-1283. doi: 10.1111/jnc.13444. Epub 2016 Jan 13.

Parkinson's disease (PD) is a debilitating condition that is caused by a relatively specific degeneration of dopaminergic (DAergic) neurons of the substantia nigra pars compacta. L-DOPA was introduced as a viable treatment option for PD over 40 years ago...

Cite
Harun R, Hare KM, Brough EM, et al. Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo. J Neurochem. 2016;136(6):1270-1283doi: 10.1111/jnc.13444.
Harun, R., Hare, K. M., Brough, E. M., Munoz, M. J., Grassi, C. M., Torres, G. E., Grace, A. A., & Wagner, A. K. (2016). Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo. Journal of neurochemistry, 136(6), 1270-1283. https://doi.org/10.1111/jnc.13444
Harun, Rashed, et al. "Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo." Journal of neurochemistry vol. 136,6 (2016): 1270-1283. doi: https://doi.org/10.1111/jnc.13444
Harun R, Hare KM, Brough EM, Munoz MJ, Grassi CM, Torres GE, Grace AA, Wagner AK. Fast-scan cyclic voltammetry demonstrates that L-DOPA produces dose-dependent, regionally selective bimodal effects on striatal dopamine kinetics in vivo. J Neurochem. 2016 Mar;136(6):1270-1283. doi: 10.1111/jnc.13444. Epub 2016 Jan 13. PMID: 26611352; PMCID: PMC4884169.
Copy Download .nbib Format: NLM
Fistulization of J-PEG Jejunal Tube into the Colon in a Patient Treated with Duodopa® Infusion: A Case Report.

GE Portuguese journal of gastroenterology

Russo P, Costa M, Silva M, de Sousa A, Carvalho D, Saiote J, Mendes M.
PMID: 28848800
GE Port J Gastroenterol. 2017 May;24(3):147-150. doi: 10.1159/000452694. Epub 2017 Jan 19.

The continuous delivery of a levodopa/carbidopa gel suspension (Duodopa®) into the small bowel through a jejunal tube inserted via percutaneous endoscopic gastrostomy represents a new treatment method in advanced Parkinson disease. Some severe device-related complications have been described in...

Cite
Russo P, Costa M, Silva M, et al. Fistulization of J-PEG Jejunal Tube into the Colon in a Patient Treated with Duodopa® Infusion: A Case Report. GE Port J Gastroenterol. 2017;24(3):147-150doi: 10.1159/000452694.
Russo, P., Costa, M., Silva, M., de Sousa, A., Carvalho, D., Saiote, J., & Mendes, M. (2017). Fistulization of J-PEG Jejunal Tube into the Colon in a Patient Treated with Duodopa® Infusion: A Case Report. GE Portuguese journal of gastroenterology, 24(3), 147-150. https://doi.org/10.1159/000452694
Russo, Pedro, et al. "Fistulization of J-PEG Jejunal Tube into the Colon in a Patient Treated with Duodopa® Infusion: A Case Report." GE Portuguese journal of gastroenterology vol. 24,3 (2017): 147-150. doi: https://doi.org/10.1159/000452694
Russo P, Costa M, Silva M, de Sousa A, Carvalho D, Saiote J, Mendes M. Fistulization of J-PEG Jejunal Tube into the Colon in a Patient Treated with Duodopa® Infusion: A Case Report. GE Port J Gastroenterol. 2017 May;24(3):147-150. doi: 10.1159/000452694. Epub 2017 Jan 19. PMID: 28848800; PMCID: PMC5553370.
Copy Download .nbib Format: NLM
Diffuse Lewy Body Disease.

Current treatment options in neurology

Zesiewicz TA, Baker MJ, Dunne PB, Hauser RA.
PMID: 11581527
Curr Treat Options Neurol. 2001 Nov;3(6):507-518. doi: 10.1007/s11940-001-0013-x.

Diffuse Lewy body disease (DLB) is a neurodegenerative disorder characterized by dementia, fluctuations in mental status, hallucinations, and parkinsonism. Diffuse Lewy body disease is the second most common cause of dementia, following Alzheimer's disease. The treatment of DLB includes...

Cite
Zesiewicz TA, Baker MJ, Dunne PB, et al. Diffuse Lewy Body Disease. Curr Treat Options Neurol. 2001;3(6):507-518doi: 10.1007/s11940-001-0013-x.
Zesiewicz, T. A., Baker, M. J., Dunne, P. B., & Hauser, R. A. (2001). Diffuse Lewy Body Disease. Current treatment options in neurology, 3(6), 507-518. https://doi.org/10.1007/s11940-001-0013-x
Zesiewicz, Theresa A., et al. "Diffuse Lewy Body Disease." Current treatment options in neurology vol. 3,6 (2001): 507-518. doi: https://doi.org/10.1007/s11940-001-0013-x
Zesiewicz TA, Baker MJ, Dunne PB, Hauser RA. Diffuse Lewy Body Disease. Curr Treat Options Neurol. 2001 Nov;3(6):507-518. doi: 10.1007/s11940-001-0013-x. PMID: 11581527.
Copy Download .nbib Format: NLM
Pharmacokinetic and clinical evaluation of liquid L-dopa/carbidopa in Parkinson's disease.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia

Marriott J, Bryant B, Kempster P, Shif M, Lewis MM, Horne M.
PMID: 18639008
J Clin Neurosci. 1998 Apr;5(2):178-81. doi: 10.1016/s0967-5868(98)90034-0.

The aim of the study was to assess the pharmacokinetic properties and clinical effectiveness of L-dopa/carbidopa solution treatment in patients with parkinsonian motor fluctuations. No significant difference in maximal L-dopa concentration, time to peak L-dopa concentration and area under...

Cite
Marriott J, Bryant B, Kempster P, et al. Pharmacokinetic and clinical evaluation of liquid L-dopa/carbidopa in Parkinson's disease. J Clin Neurosci. 1998;5(2):178-81doi: 10.1016/s0967-5868(98)90034-0.
Marriott, J., Bryant, B., Kempster, P., Shif, M., Lewis, M. M., & Horne, M. (1998). Pharmacokinetic and clinical evaluation of liquid L-dopa/carbidopa in Parkinson's disease. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 5(2), 178-81. https://doi.org/10.1016/s0967-5868(98)90034-0
Marriott, J, et al. "Pharmacokinetic and clinical evaluation of liquid L-dopa/carbidopa in Parkinson's disease." Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia vol. 5,2 (1998): 178-81. doi: https://doi.org/10.1016/s0967-5868(98)90034-0
Marriott J, Bryant B, Kempster P, Shif M, Lewis MM, Horne M. Pharmacokinetic and clinical evaluation of liquid L-dopa/carbidopa in Parkinson's disease. J Clin Neurosci. 1998 Apr;5(2):178-81. doi: 10.1016/s0967-5868(98)90034-0. PMID: 18639008.
Copy Download .nbib Format: NLM
Sleep disorders in Parkinson's disease.

Current treatment options in neurology

Comella CL.
PMID: 18579025
Curr Treat Options Neurol. 2008 May;10(3):215-21. doi: 10.1007/s11940-008-0023-z.

Sleep disorders in Parkinson's disease (PD) are frequent and have numerous etiologies. Both nighttime sleep disturbances and daytime sleepiness can occur. The key to effective treatment is appropriate diagnosis. A careful interview of the patient and his or her...

Cite
Comella CL. Sleep disorders in Parkinson's disease. Curr Treat Options Neurol. 2008;10(3):215-21doi: 10.1007/s11940-008-0023-z.
Comella, C. L. (2008). Sleep disorders in Parkinson's disease. Current treatment options in neurology, 10(3), 215-21. https://doi.org/10.1007/s11940-008-0023-z
Comella, Cynthia L. "Sleep disorders in Parkinson's disease." Current treatment options in neurology vol. 10,3 (2008): 215-21. doi: https://doi.org/10.1007/s11940-008-0023-z
Comella CL. Sleep disorders in Parkinson's disease. Curr Treat Options Neurol. 2008 May;10(3):215-21. doi: 10.1007/s11940-008-0023-z. PMID: 18579025.
Copy Download .nbib Format: NLM
Partial expression of monoaminergic (serotoninergic) properties by the multipotent hypothalamic cell line F7. An example of learning at the cellular level.

Neurochemistry international

De Vitry F, Catelon J, Dubois M, Thibault J, Barritault D, Courty J, Bourgoin S, Hamon M.
PMID: 20493099
Neurochem Int. 1986;9(1):43-53. doi: 10.1016/0197-0186(86)90030-6.

A serum-free medium supplemented with a glial conditioned medium, a brain extract from 8-to 10-day-old mice, hormones, and eye-derived growth factor has been devised which permitted the mouse primitive hypothalamic nerve cell line F7 to express some biochemical properties...

Cite
De Vitry F, Catelon J, Dubois M, et al. Partial expression of monoaminergic (serotoninergic) properties by the multipotent hypothalamic cell line F7. An example of learning at the cellular level. Neurochem Int. 1986;9(1):43-53doi: 10.1016/0197-0186(86)90030-6.
De Vitry, F., Catelon, J., Dubois, M., Thibault, J., Barritault, D., Courty, J., Bourgoin, S., & Hamon, M. (1986). Partial expression of monoaminergic (serotoninergic) properties by the multipotent hypothalamic cell line F7. An example of learning at the cellular level. Neurochemistry international, 9(1), 43-53. https://doi.org/10.1016/0197-0186(86)90030-6
De Vitry, F, et al. "Partial expression of monoaminergic (serotoninergic) properties by the multipotent hypothalamic cell line F7. An example of learning at the cellular level." Neurochemistry international vol. 9,1 (1986): 43-53. doi: https://doi.org/10.1016/0197-0186(86)90030-6
De Vitry F, Catelon J, Dubois M, Thibault J, Barritault D, Courty J, Bourgoin S, Hamon M. Partial expression of monoaminergic (serotoninergic) properties by the multipotent hypothalamic cell line F7. An example of learning at the cellular level. Neurochem Int. 1986;9(1):43-53. doi: 10.1016/0197-0186(86)90030-6. PMID: 20493099.
Copy Download .nbib Format: NLM
Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo).

Neuropsychiatric disease and treatment

Solla P, Cannas A, Marrosu F, Marrosu MG.
PMID: 20856911
Neuropsychiatr Dis Treat. 2010 Sep 07;6:483-90. doi: 10.2147/ndt.s5190.

Parkinson disease (PD) is a neurodegenerative disorder characterized by 3 cardinal motor symptoms: resting tremor, rigidity, and bradykinesia. Since its introduction 40 years ago, levodopa has represented the gold standard for dopaminergic stimulation therapy in patients with PD. Levodopa...

Cite
Solla P, Cannas A, Marrosu F, et al. Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatr Dis Treat. 2010;6:483-90doi: 10.2147/ndt.s5190.
Solla, P., Cannas, A., Marrosu, F., & Marrosu, M. G. (2010). Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatric disease and treatment, 6483-90. https://doi.org/10.2147/ndt.s5190
Solla, Paolo, et al. "Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo)." Neuropsychiatric disease and treatment vol. 6 (2010): 483-90. doi: https://doi.org/10.2147/ndt.s5190
Solla P, Cannas A, Marrosu F, Marrosu MG. Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatr Dis Treat. 2010 Sep 07;6:483-90. doi: 10.2147/ndt.s5190. PMID: 20856911; PMCID: PMC2938297.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 280 entries